FACTANKER

US-Listed In Vitro & In Vivo Diagnostic Substances — EBITDA Margin Percentiles, FY 2024

Population: 11 US-listed companies (SIC 2835), fiscal year 2024; fiscal year ends 2024-12-29 to 2025-05-31.

Fiscal year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · latest

10th percentile-443.5%
25th percentile-140.8%
Median-54.2%
75th percentile-1.7%
90th percentile32.3%
Mean-160.8%
Minimum-905.3%
Maximum34.0%
Methodology & sources
EBITDA margin = (operating income + depreciation & amortization) / revenue, all values as filed; computed in SQL per company, then percentiles. Fiscal year 2024 = fiscal years ending 2024-06-01 to 2025-05-31 (majority-overlap rule; June-ending fiscal years count toward the ending calendar year).
Source: SEC EDGAR filings (public domain). Data: FACTANKER registry, precomputed 2026-09-03.

Evidence samples

Latest EBITDA Margin percentiles (live) · All In Vitro & In Vivo Diagnostic Substances benchmarks · All industries

Cite as: FACTANKER, https://factanker.com/industries/sic-2835/ebitda-margin/2024